1. US Department of Health and Human Services. Office of Disease Prevention and Health Promotion. Healthy People 2020. Washington, DC. Available at http://www.healthypeople.gov/2020/about/qolwbabout.aspx . Accessed 1/30/14.
2. Trachtenberg, F., et al. (2011). Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American Journal of Hematology, 86(5), 433–436.
3. Sobota, A., et al. (2011). Quality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms. American Journal of Hematology, 86(1), 92–95.
4. Mednick, L., et al. (2010). Symptoms of depression and anxiety in patients with thalassemia: Prevalence and correlates in the thalassemia longitudinal cohort. American Journal of Hematology, 85(10), 802–805.
5. Yamashita, R., Sobota, A., Trachtenberg, F., Xu, Y., Quinn, C. T., Vichinsky, E. P., Haines, D., Kleinert, D. A., Schilling, L., Pakbaz, Z., Boudreaux, J., Odame, I., Thompson, A. A., Giardina, P. J., Kwiatkowski, J. L., Neufeld, E. J. (2013). The impact of the child with Thalassemia on the family: Parental assessments. in press.